Thought Leadership

Video

What the JCA means for market access in Finland?

Interview of Herbert Altmann, PhD, VP, Market Access & Healthcare Consulting Europe at PharmaLex. Finland, and the Nordics in general, have key selling points that could be highlighted to keep the region front and center. These include unique opportunities to make use of real-world data and biobanks for real-world evidence purposes.
Journal Article

Considering possible PICOs early on in clinical development is crucial

The advancement of bioinformatics has allowed for an explosion in the field of precision medicine over the last decade. There are more and more drugs that address a specific subset of patients, not least within oncology. In parallel, the centralisation process of determining clinical benefit is approaching fast, and Joint Clinical Assessment (JCA) as part of EU HTA regulation will be implemented for new oncologics and ATMPs (advanced therapy medicinal products) in January 2025. As several emerging therapies could be treatment game-changers, quick patient access without delay is of outermost importance.
Read

Start typing and press enter to search

Scroll to Top